# Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

> **NCT05432960** · PHASE3 · WITHDRAWN · sponsor: **R-Pharm International, LLC**

## Conditions studied

- Adult-Onset Still's Disease
- AOSD

## Interventions

- **BIOLOGICAL:** RPH-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05432960
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted according to the Sponsor's descision.
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432960, "Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05432960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*